These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 19454860

  • 1. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.
    Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
    [Abstract] [Full Text] [Related]

  • 2. Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
    Schwartz JI, Stroh M, Gao B, Liu F, Rosko K, Zajic S, Meehan AJ, Ruckle J, Lai E, Wagner JA.
    Cardiovasc Ther; 2009; 27(4):239-45. PubMed ID: 19903187
    [Abstract] [Full Text] [Related]

  • 3. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA.
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [Abstract] [Full Text] [Related]

  • 4. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA.
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [Abstract] [Full Text] [Related]

  • 5. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
    Liu F, Vessey L, Wenning L, Connolly S, Buckland M, Johnson-Levonas AO, Denker A, Wagner JA, Lai E.
    J Clin Pharmacol; 2010 Jul; 50(7):823-8. PubMed ID: 20197486
    [Abstract] [Full Text] [Related]

  • 6. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
    Schwartz JI, Liu F, Wang YH, Pramanik B, Johnson-Levonas AO, Gutierrez MJ, Lai E, Wagner JA.
    Am J Ther; 2009 Jul; 16(6):487-95. PubMed ID: 19940609
    [Abstract] [Full Text] [Related]

  • 7. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nunes T, Soares-da-Silva P.
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [Abstract] [Full Text] [Related]

  • 8. The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
    Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E.
    Platelets; 2011 Jan; 22(7):495-503. PubMed ID: 21526889
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
    Wang YH, Liu F, Luk JA, Nirula A, Johnson-Levonas AO, Lasseter KC, Marbury TC, Lunde NM, Wagner JA, Lai E.
    J Clin Pharmacol; 2011 Mar; 51(3):406-12. PubMed ID: 20484612
    [Abstract] [Full Text] [Related]

  • 10. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N, Kim BH, Lim KS, Kim SE, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
    Burstein AH, Clark DJ, O'Gorman M, Willavize SA, Brayman TG, Grover GS, Walsky RL, Obach RS, Faessel HM.
    J Clin Pharmacol; 2007 Nov; 47(11):1421-9. PubMed ID: 17962429
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
    Stockis A, van Lier JJ, Cawello W, Kumke T, Eckhardt K.
    Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
    [Abstract] [Full Text] [Related]

  • 19. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
    Luo WL, Crumley T, Ebel D, Atiee GJ, Royalty J, Johnson-Levonas AO, Wagner J, Lai E.
    J Clin Pharmacol; 2010 Nov; 50(11):1273-9. PubMed ID: 20107202
    [Abstract] [Full Text] [Related]

  • 20. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM.
    Am J Cardiol; 2008 Mar 01; 101(5):625-30. PubMed ID: 18308010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.